Vasculitis & polymyalgia rheumatica
Outcomes in anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis patients with end-stage kidney disease on renal replacement therapy—A meta-analysis
Authors' conclusion
Patients with AAV and ESKD have a lower risk of relapse, but higher infection and mortality rates.
Study context
- Population
- Adult patients with AAV and end-stage kidney disease (ESKD) on haemodialysis or peritoneal dialysis
- Participants
- 952 patients22 studies
- Outcome
- Mortality rate per 100 person-years (random-effects meta-analysis)
Methodological detailsrandom-effects meta-analysis
- Random-effects meta-analysis
Pooled result
As reported in the abstract
Pooled mortality rate per 100 py
Pooled mortality rate per 100 py
10.90
95% CI
7.11 - 14.68
I2
90.8%
Further pooled results
Pooled 1-year survival
- Pooled 1-year survival
- 80.9%
- 95% CI
- 75.6 - 86.1%
- I2
- 86.1%
Pooled 5-year survival
- Pooled 5-year survival
- 61.0%
- 95% CI
- 46.0 - 76.0%
- I2
- 0.0%
Pooled relapse rate per 100 py
- Pooled relapse rate per 100 py
- 6.22
- 95% CI
- 4.64 - 7.80
- I2
- 46.6%
Mortality rate, paediatric study (1 study, 9 patients)
- Deaths per 100 py (± as printed)
- 11.7 ± 1.9
- 95% CI
- 0.23 - 23.20
- Only 1 paediatric study met the inclusion criteria
Safety
- Pooled severe infection rate per 100 py
- 66.57
- 95% CI
- 13.64 - 119.50
- I2
- 99.6%
Original publication
Outcomes in ANCA-associated vasculitis patients with end-stage kidney disease on renal replacement therapy—A meta-analysis. Semin Arthritis Rheum. Published 11 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →